261762-98-5 Usage
General Description
3-Chloro-2-fluorophenylacetonitrile is an organic chemical compound with the molecular formula C8H5ClFNO. It is a white solid that is commonly used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. 3-Chloro-2-fluorophenylacetonitrile is widely employed as a precursor for the production of various pharmaceutical products, including antiviral and anticancer drugs. It is also used in the synthesis of agricultural chemicals and other organic compounds. 3-Chloro-2-fluorophenylacetonitrile is known to be a versatile building block in organic synthesis due to its ability to undergo various chemical reactions to produce a wide range of products.
Check Digit Verification of cas no
The CAS Registry Mumber 261762-98-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,6,1,7,6 and 2 respectively; the second part has 2 digits, 9 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 261762-98:
(8*2)+(7*6)+(6*1)+(5*7)+(4*6)+(3*2)+(2*9)+(1*8)=155
155 % 10 = 5
So 261762-98-5 is a valid CAS Registry Number.
InChI:InChI=1S/C8H5ClFN/c9-7-3-1-2-6(4-5-11)8(7)10/h1-3H,4H2
261762-98-5Relevant articles and documents
Preparation method of aryl acetonitrile derivative
-
Paragraph 0067-0070; 0095-0096, (2021/10/20)
The invention relates to a continuous nucleophilic addition and beta-fluorine elimination reaction method of 2,2-difluoroolefin and ammonia water in a catalyst-free and additive-free system. The method comprises the following steps: adding a 2,2-difluoroolefin compound, ammonia water and a solvent into a Schlenk reaction flask, and conducting stirring and reacting at a certain temperature in an air atmosphere to obtain the product aryl acetonitrile derivative.
NEW BICYCLIC DIHYDROISOQUINOLINE-1-ONE DERIVATIVES
-
, (2013/06/27)
The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4? R5, R6, A1, A2, A3, A4, A5 and n are as described herein,compositions including the compounds and methods of using the compounds as aldosterone synthase (CYP11B2 or CYP11B1) inhibitors for the treatment or prophylaxis of chronic kidney disease, congestive heart failure, hypertension, primary aldosteronism and Cushing syndrom.
